Replies to post #77428 on Biotech Values

[DewDiligence]

You are incorrect. They stated the competition, not specifically Tysabri. Copaxone PRIMARILY competes against the other first line treatments, the interferons, and they are the ones with the additional large price increases.

I respectfully disagree. I thought it was crystal clear from the context that the Teva executive on the CC was talking about the price of Tysabri. As a matter of policy, some companies are reluctant to refer to competing products and companies by name, and this was one such instance.